BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
The many faces of patient-pharma co-creationAhead of her appearance at eyeforpharma Barcelona, Merck’s director of patient advocacy and strategic partnerships, Vanessa Pott, tells Share XThe many faces of patient-pharma co-creationhttps://pharmaphorum.com/views-analysis-patients/the-many-faces-of-patient-pharma-co-creation-merck-eyeforpharma/
Merck, Pfizer’s Bavencio flunks head and neck cancer trialMerck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer, Share XMerck, Pfizer’s Bavencio flunks head and neck cancer trialhttps://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/
Merck partners with tech firm AMCM on tablet 3D printingMerck KGaA has partnered with German tech company AMCM to carry out clinical testing on tablets manufactured using Share XMerck partners with tech firm AMCM on tablet 3D printinghttps://pharmaphorum.com/news/merck-partners-with-tech-firm-amcm-on-tablet-3d-printing/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
Pfizer/Merck KGaA’s Bavencio set for bladder cancer advantage after phase 3 winPfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their Share XPfizer/Merck KGaA’s Bavencio set for bladder cancer advantage after phase 3 winhttps://pharmaphorum.com/news/pfizer-merck-kgaas/
NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
